Study aim: Clinical evaluation of Delayed graft function (DGF) after kidney transplantation between the vitamin C arm and the placebo Design: A double-blind, randomized clinical trial with a control group and a placebo group design of 50 patients Settings and conduct: - This study will be conducted in a double blinded clinical trial with placebo in the kidney transplantation section of Imam Khomeini Hospital. - The study will begin after the receipt of the code of ethics and receive the approval of the Ethics Committee. - Patients undergoing kidney transplants for the first time will be considered for inclusion in the study and admission criteria. - In case of informed consent, patients will be introduced. - Patients are divided into two arms of treatment with vitamin C and placebo base on Permuted Block Randomization . Participants/Inclusion and exclusion criteria: Inclusion criteria: The first kidney transplantation Deceased donor Recipient age 14 years and older Patient informed consent to enter the study Non-inclusion criteria: Hemochromatosis Documented hyperoxaluria Multi organ transplantation History of Fauvism Preemptive kidney transplantation Exclusion Criteria: Patient's dissatisfaction with the continuation of research after entering the study Intervention groups: - Patients in the treatment arm receive 70 mg/kg vitamin C (at least 3 grams) at last hour before transplant surgery. The calculated dose is diluted in 250 ml of sodium chloride solution (0.45%) and infused over an hour before the transplant. In the placebo group, placebo (a saline solution of similar volume) is prescribed at that time. Main outcome variables: dialysis in the first week after transplantation